1. Home
  2. PCRX vs MAX Comparison

PCRX vs MAX Comparison

Compare PCRX & MAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

HOLD

Current Price

$26.02

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo MediaAlpha Inc.

MAX

MediaAlpha Inc.

HOLD

Current Price

$11.73

Market Cap

722.8M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCRX
MAX
Founded
2006
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
722.8M
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
PCRX
MAX
Price
$26.02
$11.73
Analyst Decision
Strong Buy
Buy
Analyst Count
7
6
Target Price
$32.86
$17.00
AVG Volume (30 Days)
885.6K
401.0K
Earning Date
02-26-2026
02-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.47
N/A
Revenue
$716,791,000.00
$1,123,093,000.00
Revenue This Year
$6.24
$30.80
Revenue Next Year
$9.53
$8.49
P/E Ratio
$55.17
N/A
Revenue Growth
3.14
64.86
52 Week Low
$18.18
$7.33
52 Week High
$27.64
$13.92

Technical Indicators

Market Signals
Indicator
PCRX
MAX
Relative Strength Index (RSI) 56.34 35.85
Support Level $24.20 $11.37
Resistance Level $26.48 $13.09
Average True Range (ATR) 0.98 0.41
MACD -0.12 -0.16
Stochastic Oscillator 65.59 16.85

Price Performance

Historical Comparison
PCRX
MAX

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About MAX MediaAlpha Inc.

MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.

Share on Social Networks: